|
1
|
Cavalli G: Molecular biology. EZH2 goes
solo. Science. 338:1430–1431. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao Q, Mani RS, Ateeq B, et al:
Coordinated regulation of polycomb group complexes through
microRNAs in cancer. Cancer Cell. 20:187–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Leenders GJ, Dukers D, Hessels D, et
al: Polycomb-group oncogenes EZH2, BMI1, and RING1 are
overexpressed in prostate cancer with adverse pathologic and
clinical features. Eur Urol. 52:455–463. 2007.PubMed/NCBI
|
|
4
|
Ren G, Baritaki S, Marathe H, et al:
Polycomb protein EZH2 regulates tumor invasion via the
transcriptional repression of the metastasis suppressor RKIP in
breast and prostate cancer. Cancer Res. 72:3091–3104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karanikolas BD, Figueiredo ML and Wu L:
Polycomb group protein enhancer of zeste 2 is an oncogene that
promotes the neoplastic transformation of a benign prostatic
epithelial cell line. Mol Cancer Res. 7:1456–1465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bohrer LR, Chen S, Hallstrom TC and Huang
H: Androgens suppress EZH2 expression via retinoblastoma (RB) and
p130-dependent pathways: a potential mechanism of
androgen-refractory progression of prostate cancer. Endocrinology.
151:5136–5145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu K, Wu ZJ, Groner AC, et al: EZH2
oncogenic activity in castration-resistant prostate cancer cells is
Polycomb-independent. Science. 338:1465–1469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pecot CV, Calin GA, Coleman RL,
Lopez-Berestein G and Sood AK: RNA interference in the clinic:
challenges and future directions. Nat Rev Cancer. 11:59–67. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park TG, Jeong JH and Kim SW: Current
status of polymeric gene delivery systems. Adv Drug Deliv Rev.
58:467–486. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jing GJ, Fu ZG, Dan B, Lin LR, Yang TC and
Shi SL: Development and evaluation of a novel nano-scale vector for
siRNA. J Cell Biochem. 111:881–888. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Z, Liu G, Zheng H and Chen X: Rigid
nanoparticle-based delivery of anti-cancer siRNA: Challenges and
opportunities. Biotechnol Adv. Sep 5;S0734-9750(13)00154-7.
2013.(Epub ahead of print).
|
|
13
|
Mintzer MA and Simanek EE: Nonviral
vectors for gene delivery. Chem Rev. 109:259–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang W, Lv M and Gao Z: Polyethylenimine
grafted with diblock copolymers of polyethylene glycol and
polycaprolactone as siRNA delivery vector. J Control Release.
152(Suppl 1): e143–e145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weber ND, Merkel OM, Kissel T and
Muñoz-Fernández MA: PEGylated poly(ethylene imine)
copolymer-delivered siRNA inhibits HIV replication in vitro. J
Control Release. 157:55–63. 2012.PubMed/NCBI
|
|
16
|
Xu Z, Jin J, Siu LK, et al: Folic acid
conjugated mPEG-PEI600 as an efficient non-viral vector for
targeted nucleic acid delivery. Int J Pharm. 426:182–192. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Veiseh O, Kievit FM, Mok H, et al: Cell
transcytosing poly-arginine coated magnetic nanovector for safe and
effective siRNA delivery. Biomaterials. 32:5717–5725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi S, Zhu X, Guo Q, et al: Self-assembled
mPEG-PCL-g-PEI micelles for simultaneous codelivery of
chemotherapeutic drugs and DNA: synthesis and characterization in
vitro. Int J Nanomedicine. 7:1749–1759. 2012.PubMed/NCBI
|
|
19
|
Liu Y, Liu Z, Wang Y, et al: Investigation
of the performance of PEG-PEI/ROCK-II-siRNA complexes for
Alzheimer’s disease in vitro. Brain Res. 1490:43–51.
2013.PubMed/NCBI
|
|
20
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
21
|
Kirby M, Hirst C and Crawford ED:
Characterising the castration-resistant prostate cancer population:
a systematic review. Int J Clin Pract. 65:1180–1192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Min J, Zaslavsky A, Fedele G, et al: An
oncogene-tumor suppressor cascade drives metastatic prostate cancer
by coordinately activating Ras and nuclear factor-kappaB. Nat Med.
16:286–294. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan J, Yang X, Zhuang L, et al:
Pharmacologic disruption of Polycomb-repressive complex 2-mediated
gene repression selectively induces apoptosis in cancer cells.
Genes Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao R, Wang L, Wang H, et al: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu J, Yu J, Rhodes DR, Tomlins SA, et al:
A polycomb repression signature in metastatic prostate cancer
predicts cancer outcome. Cancer Res. 67:10657–10663. 2007.
View Article : Google Scholar
|
|
26
|
Bryant RJ, Cross NA, Eaton CL, Hamdy FC
and Cunliffe VT: EZH2 promotes proliferation and invasiveness of
prostate cancer cells. Prostate. 67:547–556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao P, Deng Z, Wan M, et al: MicroRNA-101
negatively regulates Ezh2 and its expression is modulated by
androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 9:1082010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takeshita F, Minakuchi Y, Nagahara S, et
al: Efficient delivery of small interfering RNA to bone-metastatic
tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA.
102:12177–12182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Monteagudo S, Pérez-Martínez FC,
Pérez-Carrión MD, et al: Inhibition of p42 MAPK using a nonviral
vector-delivered siRNA potentiates the anti-tumor effect of
metformin in prostate cancer cells. Nanomedicine (Lond). 7:493–506.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Giger EV, Castagner B, Räikkönen J,
Mönkkönen J and Leroux JC: siRNA transfection with calcium
phosphate nanoparticles stabilized with PEGylated chelators. Adv
Healthc Mater. 2:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li YH, Shi QS, Du J, et al: Targeted
delivery of biodegradable nanoparticles with ultrasound-targeted
microbubble destruction-mediated hVEGF-siRNA transfection in human
PC-3 cells in vitro. Int J Mol Med. 31:163–171. 2013.
|
|
32
|
Liu XQ, Xiong MH, Shu XT, Tang RZ and Wang
J: Therapeutic delivery of siRNA silencing HIF-1 alpha with
micellar nanoparticles inhibits hypoxic tumor growth. Mol Pharm.
9:2863–2874. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Su J, Cai W, et al:
Hepatocyte-targeting gene transfer mediated by galactosylated
poly(ethylene glycol)-graft-polyethylenimine derivative. Drug Des
Devel Ther. 7:211–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu Y, Wang W, Chen Y, et al: The
investigation of polymer-siRNA nanoparticle for gene therapy of
gastric cancer in vitro. Int J Nanomedicine. 5:129–136. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aigner A: Delivery systems for the direct
application of siRNAs to induce RNA interference (RNAi) in vivo. J
Biomed Biotechnol. 2006:716592006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang B, He ML, Xiao ZP, et al: Synthesis
and characterization of folate-PEG-grafted-hyperbranched-PEI for
tumor-targeted gene delivery. Biochem Biophys Res Commun.
367:874–880. 2008. View Article : Google Scholar : PubMed/NCBI
|
